Hisamitsu Pharmaceutical Co's EBIT per Share for the
three
months ended in Nov. 2025 was 円88.27.
Its EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2025 was 円328.68.
During the past 12 months, the average EBIT per Share Growth Rate of Hisamitsu Pharmaceutical Co was -2.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 19.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 18.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's EBIT per Share or its related term are showing as below:
FSE:4530'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -26 Med: -0.2 Max: 30.7
Current: 19.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Hisamitsu Pharmaceutical Co was 30.70% per year. The lowest was -26.00% per year. And the median was -0.20% per year.
FSE:4530's 3-Year EBIT Growth Rate is ranked better than 68.06% of 811
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs FSE:4530: 19.80
Hisamitsu Pharmaceutical Co (FSE:4530) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Hisamitsu Pharmaceutical Co EBIT per Share Related Terms
Hisamitsu Pharmaceutical Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円328.68
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a EBIT per Share of 円328.68 as of Nov. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hisamitsu Pharmaceutical Co and its competitors. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #259 out of 811 companies in the Drug Manufacturers industry, placing it in the top 31.9%.
Is Hisamitsu Pharmaceutical Co's EBIT per Share too high?
Hisamitsu Pharmaceutical Co's current EBIT per Share is 円328.68. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #259 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's EBIT per Share compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #259 out of 811 companies for EBIT per Share. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current EBIT per Share is 円328.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current EBIT per Share of 円328.68. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current EBIT per Share is 円328.68. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current EBIT per Share is 円328.68 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
EBIT per Share: 円328.68
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
